CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 Hypertension DualPathway Drugs Drive Smarter Weight Loss Fountain of Youth Presented at the ADA 85th Scientific Sessions: In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Presenters to provide first look at data from REIMAGINE trials of cagrilintide semaglutide for type 2 diabetes management ADA Meeting News Cagrilintide Combined with Semaglutide: A New Approach for Treatment of Obesity and Type 2 Diabetes ClinicSearch